

PRESS RELEASE

Lauxera Capital Partners

Lauxera Invests €50m in Acandis, a German, Neurovascular Medical Device Company Dedicated to the Prevention and Treatment of Stroke

Pforzheim, Paris & San Francisco,

January, 22, 2025

Lauxera Capital Partners' Acandis transaction is the firm's first investment out of Lauxera Growth II, its second-generation healthcare growth buyout fund.

Founded in 2006 by Dr. Andreas and Kirsi Schuessler, Acandis is a leading neurovascular medical device platform. With state-of-the-art manufacturing facilities and commercial operations in more than 60 countries, Acandis is fully vertically-integrated and rapidly growing. The company is headquartered in Pforzheim, Germany and employs more than 300 people.

Since its inception, under the leadership of its founders and management team, Acandis has demonstrated an aptitude for continuous innovation, establishing itself as a pioneer in the flow diverter, rescue stenting, mechanical thrombectomy and biologically-active device coating fields.

The company has launched 17 product families with an emphasis on improving patient outcomes and procedure ease. Because of Acandis product's unique features and benefits, the company has achieved market leadership in multiple geographies. Excellence in stent design has enabled the company to produce an unprecedented range of device sizes, all seemingly tailor made to patient anatomy.

With a compound annual growth rate (CAGR) exceeding 25% since 2021, Acandis is well-positioned to outpace the fast-growing global neurovascular medical device market. The company has delivered this growth profile while remaining highly profitable.

Lauxera Growth II and Acandis Partnership

Acandis is the inaugural investment of Lauxera Growth II, a growth buyout successor fund which commenced fundraising in Q3 2024. With its first close in December, 2024, the vehicle has already substantially surpassed the size of its predecessor vehicle, Lauxera Growth I, a €262 million fund.

Dr. Andreas & Kirsi Schuessler, Acandis Co-Founders commented: *“After interacting with numerous investment firms, we decided to partner with Lauxera because of their deep experience developing and commercializing medical devices, their humility, ‘can-do’ attitude, and strong links to the US market. It felt like a true partnership from the first day Lauxera started due diligence and we are excited to build our family business alongside Sam, Edoardo and the broader Lauxera team.”*

Dr. Samuel Levy, Founding Partner at Lauxera added: *“What Kirsi and Andreas have accomplished at Acandis over the past 19 years is a remarkable medical device entrepreneurial success story. They have brought numerous classes of innovative medical devices to market both saving lives and delighting physician customers. Our goal is to help Kirsi and Andreas successfully lead the next chapter of the company’s extraordinary growth journey.”*

Edoardo Fracchia, Partner at Lauxera further added: *“Acandis’ ability to combine robust, consistent growth, manufacturing excellence, and superior research and innovation—while maintaining flexibility and agility—truly reflects the founders’ motto: ‘We always give every good idea a chance.’”*

Key uses of funds from the transaction include accelerating commercialization activities in direct markets and executing US clinical trials to achieve US market access for key Acandis products. The company will also explore external growth opportunities to broaden its reach and deepen its portfolio.

About Lauxera Capital Partners:

Founded in 2020, Lauxera Capital Partners is a leading transatlantic investment firm exclusively dedicated to the healthtech industry. Led by entrepreneurial company builders and seasoned investors, Lauxera has guided healthcare companies through every stage of growth. The firm currently manages over €600 million in assets (AuM) via two growth buyout investment vehicles. Lauxera Growth I supports 12 portfolio companies acting as a strong operational and financial partner to drive both organic and external growth. Lauxera Growth II builds on the same investment strategy as its predecessor, offering larger equity checks to expand reach and accelerate medical innovation globally. Since its founding, Lauxera Capital Partners has championed investing for impact. The firm is committed to delivering positive outcomes for patients, providers, and healthcare systems through its portfolio companies and its “Carried for Interest” program, which supports charitable healthcare organizations.

About Acandis GmbH:

Founded in 2006, Acandis is a German medical device company which manufactures and commercializes highly-innovative interventional devices for the treatment of neurovascular diseases. The company offers a comprehensive portfolio of cutting-edge, lifesaving products composed of stents, thrombectomy devices, flow diverters, and catheters, addressing both ischemic and haemorrhagic strokes. Acandis' active innovation engine has yielded numerous proprietary technologies that enhance device effectiveness, user-friendliness, and patient outcomes. The company maintains a strong intellectual property portfolio. Headquartered in Pforzheim, Baden-Württemberg, Germany, Acandis has a global footprint with presence in Europe, Asia, India, and South America.

Press Contact:

Lise de Courville

ldecourville@laxera.com